Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156367 | 0.88 | KDM4E (0.43) | L3MBTL1KDM4EPIM1HPGDDAO | |
| SCHEMBL4162503 | 0.82 | HPGD (0.56) | KDM4EHPGDDAOPOLB | |
| SCHEMBL4158442 | 0.78 | KDM4E (0.48) | L3MBTL1KDM4EADRA1DGRIN1GRIN2B | |
| SCHEMBL4163074 | 0.78 | L3MBTL1 (0.50) | L3MBTL1ADRA1DGRIN1GRIN2BROCK2 | |
| SCHEMBL4173284 | 0.77 | HPGD (0.43) | L3MBTL1FEN1HPGDPOLB | |
| SCHEMBL4156291 | 0.76 | FEN1 (0.47) | L3MBTL1KDM4EPIM1GRIN1GRIN2B | |
| SCHEMBL2496260 | 0.69 | P2RY2 (0.41) | L3MBTL1KDM4EPIM1HPGDDAO | |
| SCHEMBL2492788 | 0.69 | P2RY2 (0.40) | L3MBTL1KDM4EHPGDPOLB | |
| SCHEMBL7359634 | 0.67 | L3MBTL1 (0.57) | L3MBTL1KDM4EADRA1DROCK2 | |
| SCHEMBL23849818 | 0.67 | ACMSD (0.76) | L3MBTL1KDM4EHPGDACMSDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2009-06-11 | — | — | US | disclosed |
| WO-2007122634-A2 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122634-A2 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149485-A1 | PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS | TK1, LCK, FYN | L3MBTL1 4829/4885KDM4E 2284/4885PIM1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.